To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
Reuters file photo The Pfizer logo is seen at an office in Belgium in December 2022.
The Yomiuri Shimbun
15:05 JST, September 2, 2023
The Health, Labor and Welfare Ministry gave special approval for the manufacture and sale of Pfizer Inc.’s vaccine for XBB.1.5, a new omicron variant of the novel coronavirus, in Japan on Friday.
Those 6 months or older will be eligible to receive the U.S. pharmaceutical company’s vaccine. Inoculations will begin on Sept. 20 in preparation for the expected spread of coronavirus infections during the year-end and New Year’s holidays.
The shots will be administered for free during fiscal 2023.
